Regeneron Pharmaceuticals And Sanof's Dupixent (dupilumab) sBLA Accepted For FDA Priority Review For Treatment Of Adolescents With Chronic Rhinosinusitis With Nasal Polyposis (CRSwNP)
Author: Benzinga Newsdesk | May 13, 2024 03:00am
If approved, Dupixent would be the first treatment in the U.S. indicated for adolescents aged 12-17 years with inadequately controlled CRSwNP, a condition driven in part by underlying type 2 inflammation that obstructs the sinuses and nasal passages and can lead to a loss of sense of smell
Current treatment options for adolescents with CRSwNP leave many patients with uncontrolled disease and often result in the recurrence of nasal polyps